TMDX - Organ Transplant-Focused TransMedics Stock Soars Solid Q3 Performance In Focus | Benzinga
TransMedics Group Inc (NASDAQ: TMDX) reported Q3 revenues of $66.4 million, a 159% Y/Y increase, beating the consensus of $49.19 million.
The increase was due primarily to greater utilization of the company's NOP across all three OCS products and the addition of logistics and aviation revenue.
Revenue from the new, transplant-related aviation and logistics offerings was $2.1 million. Additionally, total revenue ...